Daratumumab,Talquetamab,Teclistamab,Pomalidomide
Genmab,Janssen
['mmsm']
aa3/ infection rate all grade:70%, g3/4:25%. 11% had opportunistic infxn, 1.5% death due to infection, 95% received px, 33% received ivig. no data regarding hospitalization due to infection #mmsm #myeloma #medtwitter #meded #asco23 #usmirc 
Associate Professor,Plasma Cell disorder program Director, Division of HMCT/University of Kansas Medical Center, no COI, #USMIRC Founder, #mmsm @KUMedCenter